KCNA1 gain-of-function epileptic encephalopathy treated with 4-aminopyridine

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Precision medicine is revolutionizing the treatment of Mendelian epilepsy.
• Early infant epilepsy often presents as pharmacoresistant multifocal epilepsy.

Purpose of the Study:

• To identify the genetic cause of severe pharmacoresistant epilepsy in an infant.
• To investigate the functional impact of a novel KCNA1 variant.
• To evaluate the therapeutic potential of 4-aminopyridine.

Main Methods:

• Exome sequencing to identify genetic variants.
• Functional studies in oocytes to assess channel function.
• Clinical evaluation of 4-aminopyridine treatment.

Main Results:

• A de novo variant, p.(Leu296Phe), in the KCNA1 gene was identified.
• Functional studies revealed a gain-of-function mutation in the K_V 1.1 channel.
• The mutated channels showed sensitivity to 4-aminopyridine.
• Clinical treatment with 4-aminopyridine significantly reduced seizure burden and medication complexity.

Conclusions:

• The identified KCNA1 gain-of-function variant is a novel cause of severe infantile epilepsy.
• 4-aminopyridine is a promising targeted therapy for epilepsy caused by KCNA1 gain-of-function mutations.
• This case highlights the success of precision medicine in treating rare genetic epilepsies.